Key Details
Price
$3.75Annual Revenue
$309.20 MAnnual EPS
-$3.69Annual ROE
-77.77%Beta
1.12Events Calendar
Next earnings date:
Mar 14, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Mar 14, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Cardlytics (CDLX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ: CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SAN FRANCISCO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Cardlytics, Inc. (NASDAQ: CDLX) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Cardlytics, Inc. (NASDAQ: CDLX) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.
FAQ
- What is the primary business of Cardlytics?
- What is the ticker symbol for Cardlytics?
- Does Cardlytics pay dividends?
- What sector is Cardlytics in?
- What industry is Cardlytics in?
- What country is Cardlytics based in?
- When did Cardlytics go public?
- Is Cardlytics in the S&P 500?
- Is Cardlytics in the NASDAQ 100?
- Is Cardlytics in the Dow Jones?
- When was Cardlytics's last earnings report?
- When does Cardlytics report earnings?
- Should I buy Cardlytics stock now?